Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AbCellera Biologics Inc.
Report date September 23, 2021 · Filed September 24, 2021
Section 16 reporting ended · disclosed 2021-09-24. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2021 Filed Sep 3, 2021 20:18 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare option (right to buy) · Derivative | 875,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-21-054749 · doc4.xml · derivative · entry 2 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Shares · 875,000 shares Expires 2029-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on January 1, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:18 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 875,000 | $16.89 | $14,778,750.00 |
DisclosureSEC source: 0001209191-21-054749 · doc4.xml · nonDerivative · entry 1 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 21:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | SaleCommon Shares | 1,000,000 | $25.50 | $25,500,000.00 |
DisclosureSEC source: 0000899243-21-022987 · doc4.xml · nonDerivative · entry 1 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · shares: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. F1 · price: On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50. Read SEC document |
| March 19, 2021 Filed Apr 24, 2021 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionShare Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0000899243-21-016935 · doc4.xml · derivative · entry 2 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,000,000 shares Expires 2025-08-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $0.0450 using an exchange rate on August 4, 2015 of CAD $1.313 = US $1.00. F2 · derivative.exercise_date: As of the date of the transaction, the option was fully vested and exercisable. Read SEC document |
| March 19, 2021 Filed Apr 24, 2021 00:00 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | Exercise / conversionCommon Shares | 1,000,000 | $0.03 | $34,300.00 |
DisclosureSEC source: 0000899243-21-016935 · doc4.xml · nonDerivative · entry 1 Falconer Ester · CIK 0001844479 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.